Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In

[1]  E. Vicaut,et al.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. , 2013, The New England journal of medicine.

[2]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[3]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[4]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[5]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[6]  A. Jaffe,et al.  Why all the struggle about CK-MB and PCI? , 2012, European heart journal.

[7]  Marc P. Bonaca,et al.  ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial , 2011 .

[8]  J. Tanguay,et al.  From primary to secondary percutaneous coronary intervention: the emerging concept of early mechanical reperfusion with delayed facilitated stenting-when earlier may not be better. , 2011, The Canadian journal of cardiology.

[9]  D. Yellon,et al.  Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. , 2011, European heart journal.

[10]  G. Stone,et al.  Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention , 2010, Circulation. Cardiovascular interventions.

[11]  C. Cannon,et al.  Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis , 2010, Circulation.

[12]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[13]  E. Antman,et al.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.

[14]  N. Danchin,et al.  Pre-hospital thrombolysis in perspective. , 2008, European heart journal.

[15]  E. Antman,et al.  Biomarker release after percutaneous coronary intervention: a message from the heart. , 2008, Circulation. Cardiovascular interventions.

[16]  M. Sabatine,et al.  Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. , 2008, American heart journal.

[17]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[18]  D. Yellon,et al.  Myocardial reperfusion injury. , 2007, The New England journal of medicine.

[19]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[20]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[21]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[22]  S. Yusuf,et al.  Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. , 2005, American heart journal.

[23]  G. Filippatos,et al.  Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. , 2005, European heart journal.

[24]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[25]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[26]  M. Burritt,et al.  Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. , 2004, Chest.